Achieve Life Sciences announces pricing of $45.0 million underwritten public offering. Learn more:
With @Omnicom, we've outlined a launch strategy for the first potential new treatment for nicotine dependence in 20 years. With proven, cross-industry insights, we aim to set a ...new standard for biotech and help millions who want to quit.
Learn more: https://bit.ly/AchieveOmnicom
Today, Achieve announced that it has submitted a New Drug Application to the @US_FDA for cytisinicline as a treatment of nicotine dependence for smoking cessation. We are thrilled... to have taken this next step. Read more: https://bit.ly/AchieveNDA
Recently, our CEO, Rick Stewart, joined Justin Walsh, Director, Research Analyst at JonesTrading, to discuss the critical need for innovation in the smoking cessation market and ...how Achieve is working to address nicotine dependence.
Register and watch the full recording at…
Join us today at 5:30 PM ET as our CEO, Rick Stewart, presents Achieve Life Sciences' efforts to address nicotine dependence and support individuals on their journey to quit ...smoking.
Watch the live webcast and recording at: https://ir.achievelifesciences.com/
The ORCA-3 Phase 3 trial results for our investigational treatment, cytisinicline, recently published in @JAMAInternalMed, highlighted the need for new treatment options.
What do... you think is the biggest challenge to quitting smoking? Read more:
We’re excited to announce that Achieve Life Sciences will participate in the @Jefferies Global Healthcare Conference.
We’ll share updates on our progress addressing nicotine... dependence as a treatment for smoking cessation. Read more at https://bit.ly/AchieveJefferiesHealthcare…
Today, Achieve Life Sciences will present new data from our Phase 3 ORCA-3 trial results during an oral session at the 2025 @atscommunity’s International Conference.
For ...more details, read the full press release:
#ATS2025
We’re thrilled to be in San Francisco, attending the @atscommunity’s International Conference! Are you attending #ATS2025? If you’re interested in meeting with us, please ...send an email to ir@achievelifesciences.com.
Don’t miss Dr. Mark Rubinstein’s presentation on new data from our Phase 3 studies at the @atscommunity’s International Conference!
Learn how cytisinicline, our ...investigational treatment, is advancing smoking cessation research.
#ATS2025
04.16.26
Press Release
$180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA Approval Transaction led by Frazier Life Sciences, TPG Life Sciences Innovations, venBio Partners, Paradigm BioCapital Advisors and Marshall Wace SEATTLE, Wash. and VANCOUVER, British Columbia, April 16, 2026 (GLOBENEWSWIRE) – Achieve Life Sciences, Inc. (Nasdaq: ACHV),…
/Read More04.16.26
Press Release
Achieve Names Two New Exemplary Healthcare Leaders to its Board of Directors New Leadership and Financing, up to $354 Million ($180 Million Upfront and $174 Million Dependent on the Exercise of Milestone Warrants), Strengthen Achieve’s Position to Execute Development and Launch of Cytisinicline, if Approved, as the First New Treatment for Nicotine Dependence in Two…
/Read More04.15.26
Press Release
Adare Partnership Provides Supply Chain Redundancy and U.S.-based Manufacturing Capability Company Reiterates Guidance – If Approved, Cytisinicline Commercial Launch Expected in First Half of 2027 SEATTLE and VANCOUVER, British Columbia, April 15, 2026 (GLOBENEWSWIRE)– Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and…
/Read More03.26.26
Press Release
Preclinical findings show cytisinicline’s minimal 5-HT3 serotonin receptor binding offers insight into observed low nausea rates in smoking and vaping cessation trials SEATTLE and VANCOUVER, British Columbia, March 26, 2026 (GLOBENEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced the…
/Read More03.24.26
Press Release
Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today, March 24, 2026 SEATTLE and VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Achieve) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine…
/Read More
;